Kenya: A case study
Access to paediatric HIV drug formulations: Nancy’s perspective
1.6 million people live with HIV in Kenya, including 110 000 children. As a child, what are your HIV treatment options? One that is adapted for your needs, not bitter and not too big? None.
Nancy Auma Juma, a young person from Kibera, Nairobi, and living with HIV since birth, reminds us that a lot still remains to be done to accelerate the development and uptake of the most needed drug formulations for children.
UKRAINE: A case study
Making HIV and viral hepatitis treatments accessible
Ukraine has the second largest HIV epidemic in Eastern Europe and Central Asia. And nearly 1.5 million people in the country are living with hepatitis C.
How do you get affordable quality medicines to these people in need?
This January, MPP visited Ukraine to engage with partners – from patients to medical experts, from originators to generic manufacturers, from civil society to the WHO and many more. Unleashing the power of partnership, MPP’s licences have led to the supply of over 20,000 courses of hepatitis C treatments and 1.5 million packs of DTG and combination products for HIV treatment in Ukraine.
